# Corvus Pharmaceuticals (CRVS) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/CRVS
## Company Profile
- Ticker: CRVS
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Antibody Drugs, Oncology
## Stock Data
- Close: 13.86 USD
- Market cap: 983017056.56 USD
- Last updated: 2026-08-06
## Business Overview
### ITK Inhibition
Corvus Pharmaceuticals develops therapies based on inhibition of interleukin-2-inducible T-cell kinase, or ITK. The approach is intended to rebalance immune-cell activity in inflammatory diseases and cancer.
### Soquelitinib
Soquelitinib is an oral, selective ITK inhibitor. Its lead immunology program is a Phase 2 study in moderate-to-severe atopic dermatitis, supported by Phase 1 evidence of clinical activity and post-treatment responses.
### Oncology Applications
Corvus is also evaluating ITK biology in oncology, where modulating T-cell differentiation and function may provide a distinct immunotherapeutic mechanism.
## Why The Stock Is Moving

The latest monitored company update is “Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- Final Phase 1 atopic-dermatitis data for soquelitinib at the SID Annual Meeting in May 2026.

## Recent News
- 2026-08-06 20:01 EST — [Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-second-quarter-2026--e0de761b) — Source: Corvus Pharmaceuticals
- 2026-07-30 20:01 EST — [Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026](https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-to-provide-business-update-and-second-quarter-2026-financ-46f83caa) — Source: Corvus Pharmaceuticals
- 2026-06-09 11:30 EST — [Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China](https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-announces-additional-investment-in-angel-pharmaceuticals--ebda81bd) — Source: Corvus Pharmaceuticals
- 2026-05-20 20:01 EST — [Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-2026-jefferies-global-healthcare-conference-and-goldman-sachs-47th-annual-global-healthcare-conference) — Source: Corvus Pharmaceuticals
- 2026-05-14 11:00 EST — [Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting](https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-presents-soquelitinib-phase-1-atopic-dermatitis-data-at-the-society-for-investigative-dermatology-sid-annual-meeting) — Source: Corvus Pharmaceuticals